Approval · Notice of Compliance 8021 · 2006
RAN-RISPERIDONE: Notice of Compliance 8021
Issued June 13, 2006
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 8021
- Date
- June 13, 2006
- Company
- Ranbaxy Pharmaceuticals Canada Inc.Brampton, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- Admin
- Reason
- New manufacturer and product name
- Therapeutic class
- Antipsychotic
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| RAN-RISPERIDONE | 02280906 | Cancelled Post Market |
| RAN-RISPERIDONE | 02280914 | Cancelled Post Market |
| RAN-RISPERIDONE | 02280922 | Cancelled Post Market |
| RAN-RISPERIDONE | 02280930 | Cancelled Post Market |
| RAN-RISPERIDONE | 02280949 | Cancelled Post Market |
| RAN-RISPERIDONE | 02280957 | Cancelled Post Market |
Medicinal ingredients
- RISPERIDONE 0.25 MG per TAB
- RISPERIDONE 0.5 MG per TAB
- RISPERIDONE 1 MG per TAB
- RISPERIDONE 2 MG per TAB
- RISPERIDONE 3 MG per TAB
- RISPERIDONE 4 MG per TAB